Keyphrases
Inflammatory Bowel Disease
100%
Kinase Signaling
33%
Colitis-associated Cancer
33%
Janus Kinase Inhibitors
33%
JAK1 Inhibitor
33%
Metabolomics
33%
Tofacitinib
22%
Inflammation
17%
Chronic Inflammatory Diseases
17%
Kinase Cascade
13%
Jakinibs
11%
Breaking New Ground
11%
Oral Small Molecules
11%
Janus Kinase
11%
Third Generation
11%
Treatment Course
11%
Inflammatory Bowel Disease Treatment
11%
Safe Treatment
11%
Pathophysiology
11%
Cardiovascular Complications
11%
Venous Thromboembolism
11%
Human Studies
11%
Clinical Opportunities
11%
Therapeutic Potential
11%
Pulmonary Embolism
11%
Janus Kinase 1 (JAK1)
11%
Novel Targeted Therapy
11%
Serious Adverse Events
11%
Mechanism of Action
11%
Serious Adverse Effects
11%
Drug Class
11%
Multi-omics
11%
Systems Biology
11%
JAK-STAT Pathway
6%
Cyclin-dependent Kinase
6%
Autophagy
6%
Cancer Development
6%
Colon Cancer
6%
Chronic Inflammation
6%
JAK-STAT
6%
Colorectal Cancer
6%
Therapeutic Landscapes
6%
Mitogen-activated Protein Kinase
6%
Gastrointestinal Tract
6%
JAK Inhibitors
6%
Colon
6%
Cellular Processes
6%
Degree of Circularity
6%
Organoid Morphology
6%
Intestinal Healing
6%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
73%
Inflammation
35%
Colon Cancer
33%
Colitis
33%
Phosphotransferase
33%
Ulcerative Colitis
33%
Janus Kinase Inhibitor
31%
Adverse Event
16%
Tofacitinib
16%
Venous Thromboembolism
8%
Janus Kinase
8%
Combination Therapy
8%
Inflammatory Disease
8%
Lung Embolism
8%
Pathophysiology
8%
Cardiovascular Disease
8%
Cytokine
8%
Biological Product
8%
Human Study
8%
Disease
6%
Colorectal Cancer
6%
Mitogen Activated Protein Kinase
6%
Cyclin Dependent Kinase
6%
Cellular Processes
6%
Malignant Neoplasm
6%
Chronic Inflammation
6%
Diseases
6%
Prednisolone
6%
Enteropathy
6%
Clinical Study
6%
Glucocorticoid
6%
RNA-Sequencing
6%
Medicine and Dentistry
Inflammatory Bowel Disease
33%
Organoid
33%
Epithelial Cell
33%
Patient with Ulcerative Colitis
33%
Colon
26%
Intestinal Stem Cell
26%
Ulcerative Colitis
26%
Janus Kinase Inhibitor
25%
In Vitro
20%
Tofacitinib
16%
Adverse Event
16%
Venous Thromboembolism
8%
Cardiovascular Disease
8%
Cytokine
8%
Pulmonary Embolism
8%
Combination Therapy
8%
Inflammatory Disorder
8%
Targeted Therapy
8%
Human Study
8%
Pathophysiology
8%
Janus Kinase
8%
Biological Product
8%
Sigmoid
6%
Gene Expression
6%
Prednisolone
6%
Enteropathy
6%
Diseases
6%
Biopsy Technique
6%
RNA Sequence
6%
Stem Cell
6%
Patient with Inflammatory Bowel Disease
6%
Colonoscopy
6%
Glucocorticoid
6%
Clinical Study
6%
